Revolution Medicines (RVMD) Accumulated Expenses (2019 - 2026)

Revolution Medicines has reported Accumulated Expenses for 8 years, with the latest figure at $5.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 62.81% year-over-year to $5.0 million; the trailing twelve-month figure through Mar 2026 stood at $5.0 million (down 62.81% YoY), and the FY2025 full-year result was $209.3 million, up 116.67% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $5.0 million, down from $209.3 million in the prior quarter.
• The five-year high for Accumulated Expenses was $256.5 million in Q3 2025, with the low at $5.0 million in Q1 2026.
• Average Accumulated Expenses over 5 years is $65.8 million, with a median of $42.6 million recorded in 2023.
• Peak annual rise in Accumulated Expenses reached 549.92% in 2023, while the deepest fall reached 77.11% in 2023.
• Tracing RVMD's Accumulated Expenses over 5 years: stood at $29.4 million in 2022, then soared by 153.66% to $74.7 million in 2023, then increased by 29.35% to $96.6 million in 2024, then surged by 116.67% to $209.3 million in 2025, then plunged by 97.61% to $5.0 million in 2026.
• The last three Accumulated Expenses figures came in at $5.0 million (Q1 2026), $209.3 million (Q4 2025), and $256.5 million (Q3 2025), per Business Quant data.

Peer Comparison